Dr. Steven Pipe completed his undergraduate medical training at the University of Toronto, and his pediatric training at McMaster University in Hamilton, Ontario. He came to the University of Michigan ...
Education and Training
Univ of Toronto, Fac of Med, Toronto, Ont, Canada 1989
University Of Toronto Faculty Of Medicine 1989
PediatricsAmerican Board of PediatricsABP
DermatologyAmerican Board of DermatologyABD
- Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII.
- Regulation of factor VIII expression and activity by von Willebrand factor.
- A chamber of hope for hemophilia.
- Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.
- Inferior vena cavectomy for nonexcisable Wilms' tumor thrombus.
- Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs.
- Neonatal sinovenous thrombosis associated with homozygous thermolabile methylenetetrahydrofolate reductase in both mother and infant.
- Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.
- The future of recombinant coagulation factors.
- Tricuspid valve thrombus and pulmonary embolus in an infant with homozygous thermolabile methylenetetrahydrofolate reductase and heterozygous prothrombin G20210A variant.
- LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII.
- Bioengineering of coagulation factor VIII for improved secretion.
- Coagulation factors with improved properties for hemophilia gene therapy.
- New high-technology products for the treatment of haemophilia.
- The promise and challenges of bioengineered recombinant clotting factors.
- The physician's role in selecting a factor replacement therapy.
- Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
- Strategies towards a longer acting factor VIII.
- Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment.
- International workshop on immune tolerance induction: consensus recommendations.
- The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.
- Optimizing outcomes for patients with severe haemophilia A.
- Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors.
- Bleeding disorders.
- Post-thrombotic syndrome in children: a single center experience.
- Recombinant clotting factors.
- Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A.
- Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
- Progress in the molecular biology of inherited bleeding disorders.
- Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.
- Antioxidants reduce endoplasmic reticulum stress and improve protein secretion.
- Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
- Functional roles of the factor VIII B domain.
- Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study.
- Go long! A touchdown for factor VIII?
- In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.
- Hemophilia: new protein therapeutics.
- Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.
- Functional factor VIII made with von Willebrand factor at high levels in transgenic milk.
- Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop.
- The hope and reality of long-acting hemophilia products.
- Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.
- Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
- A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
- Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine.
- Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care.
- New therapies for hemophilia.
- Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.
- Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.
- A Cornucopia of Therapies under Study for Hemophilia.
- Gene therapy for hemophilia.
- Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
- Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII.
- Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.
- Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin.
- Biosynthesis, assembly and secretion of coagulation factor VIII.
- Can we improve on nature? "Super molecules" of factor VIII.
- Fellow Royal College of Physicians
- Univ Of Mi Hosps & Hlth Ctrs, Pediatric Hematology-Oncology
- McMaster University Affiliated Hospitals 1993
- University of Michigan Program
- Pediatric Hematology/Oncology, University of Michigan Health System 1994
- Pediatric Scientist Development Program, University of Michigan Health System 1997
Dr. Steven W Pipe MD's Practice location
Ann Arbor, MI 48109Get Direction
Dr. Steven W Pipe MD's reviewsWrite Review
- What is Hand, Foot, and Mouth Disease?
This mild viral disease most commonly seen in children is caused by enterovirus. Hand, foot, and mouth disease may happen in adults as well. It is characterized by sores in the mouth, hands, and legs and usually lasts for a few weeks. The disease is more common during the summer and fall. This...
- Diversifying Healthcare: Male and Minorities as Nurses
In November 1854, Florence Nightingale, with a slew of volunteer nurses that she had trained, arrived to aid the wounded during the Crimean War. This incident catapulted women into the nursing industry and became a staple for many years to come. ...
- How Is Leukemia Diagnosed?
Leukemia in its early stages may present no signs or symptoms, as these only appear when the leukemia cells have taken over a large number of normal blood cells. A person with leukemia is very lucky indeed if early-stage detection occurs incidentally, through a routine blood test or one done for...
- Potential Causes of Leukopenia
IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...
- Study Finds 3% of Pediatric Non-Hodgkin Lymphoma Cases Are Transplant Recipients
Lymphoma is a blood cancer that affects both children and adults.Lymphoma begins its growth in the lymphatic white blood cells of the lymph system. This system is a major warrior in fighting off infections and diseases. It is part of the body’s immunity team.The lymph system loops throughout the...
PurpuraPurpura refers to purple-colored spots that are usually seen on the skin, including mucous membranes and other organs. It is also called skin hemorrhages or blood spots.Purpura is usually recognized when there is pooling of blood under the skin due to ruptured small blood vessels. The size of...
- Dr. Aghiad Chamdin MD1500 East Medical Center Dr Ann Arbor MI 48109
- Dr. Valerie P Opipari MD1500 East Medical Center Dr Ann Arbor MI 48109
- Dr. Jordan A Shavit MD1500 East Medical Center Dr Ann Arbor MI 48109
- Dr. Andrew D Campbell MD1500 E Medical Center Dr Ann Arbor MI 48109
- Rajen J Mody MB BS1500 East Medical Cneter Dr Ann Arbor MI 48109
- Dr. Andrew C Harris M.D.1500 E Medical Center Drive Ann Arbor MI 48109